Jason Harris

Rucaparib was associated with superior outcomes among women with ovarian cancer harboring a non-BRCA homologous recombination repair gene mutation compared with placebo, according to an analysis of specimens collected in the phase III ARIEL3 trial (NCT01968213).

Veliparib plus chemotherapy extended progression-free survival for BRCA wild-type patients with high-grade serous carcinoma.

Cholangiocarcinoma is both rare and aggressive, and the current systemic standard of care, gemcitabine plus cisplatin, produces only modest results.

Like all fellowship directors, Gerald Hsu, MD, PhD, is looking for applicants with intelligence, ambition, and a desire to advance cancer research and clinical care.

Clara D. Bloomfield, MD, the 2015 Giants of Cancer® award winner for Myeloid Neoplasms and a revolutionary physician-scientist, died March 1 at the age of 77.

There are clear biomarkers available to guide treatment decisions in the second-line setting for patients with advanced hepatocellular carcinoma, Lipika Goyal, MD, Mphil, said during a presentation at the 2020 HCC-TAG Conference.

By 2025, Anthony El-Khoueiry, MD, expects to see a larger menu of approved drugs and drug combinations for the treatment of advanced hepatocellular carcinoma, better use of molecular and immune signatures to guide treatment decisions, and, possibly, the chance to cure intermediate- and advanced-stage disease.

Following a series of negative phase III single-agent trials in hepatocellular carcinoma, investigators are finding better results with immunotherapy combination regimens.

Clinical evidence shows that patients with hepatocellular carcinoma who receive care that incorporates multiple providers from a variety disciplines leads to better results.

Richard S. Finn, MD, reflects on data from the phase III REFLECT, RESORCE, CELESTIAL, and REACH-2 trials in hepatocellular carcinoma.

Findings from the phase III IMbrave 150 trial represented the first time a treatment outperformed sorafenib for overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC), and the HCC world was understandably excited, said Ghassan K. Abou-Alfa, MD.

Chemotherapy in combination with immunotherapy holds promise in the treatment paradigm for patients with ovarian cancer, Floor Backes, MD, said at the 2020 SGO Winter Meeting.

With few chemotherapy options available for patients with cervical cancer, R. Wendel Naumann, MD, said that immunotherapy represents an attractive treatment option in the landscape.

Tumors from a significant percentage of patients with endometrial cancer at NYU Langone Health’s Perlmutter Cancer Center were found to have BRCA1/2 somatic mutations.

In ovarian cancer, disease that returns within 6 months of treatment following platinum-based therapy is defined as platinum-sensitive.

Researchers and practicing physicians have done as much as possible with chemotherapy as a systemic treatment for endometrial cancers, and other modalities—alone and in combination—are likely to become standard of care in the coming years, Shannon N. Westin, MD, MPH, said during a presentation at the 2020 SGO Winter Meeting.

Maintenance treatment with PARP inhibitors should be the standard of care in the frontline setting for patients with ovarian cancer, Kathleen M. Moore, MD, said during a presentation at the 2020 Society of Gynecologic Oncology Winter Meeting.

Although most breast tumors are not immunogenic, evidence indicates that triple-negative breast cancer expressing PD-L1 is a strong candidate for immunotherapy, explained Leisha A. Emens, MD, PhD, in a presentation on recent trials of immunotherapy alone and in combination with anti–PD-1 therapy.

The 37th Annual Miami Breast Cancer Conference provides practical guidance on cutting-edge developments in the treatment of breast cancer.

The standard of care in the second line for patients with mismatch repair–deficient metastatic colorectal cancer has shifted to favor therapy utilizing immunotherapeutic agents, according to Howard Hochster, MD.

The advent of immunotherapy options to treat patients with cancer has brought with it a new wave of immuno-related toxicities. One institution, Massachusetts General Hospital, has taken steps to establish an immunotherapy toxicity service care team, inspired by a 65-year-old patient with metastatic melanoma that had spread to his lungs and brain.

A pair of fellows will be able to advance their innovative technology-based projects thanks to the OncLive® Innovation Challenge: Innovative Technology in Cancer Care.

Estrogen alone as menopausal hormone therapy was found to decrease breast cancer incidence in postmenopausal women.

The aromatase inhibitor anastrozole maintained a preventive effect for postmenopausal women at high risk for breast cancer nearly 12 years after discontinuing treatment.

Adding the novel oral fluoropyrimidine derivative S-1 to adjuvant endocrine therapy significantly improved invasive disease-free survival for Japanese patients with HR-positive, HER2-negative breast cancer.

About 20% of fitness apps reviewed in a recent study were deemed appropriate for survivors of cancer, showing that they could be an effective tool in helping this population increase physical activity.

Focusing on the needs of patients with cancer who were likely to be “superutilizers” of healthcare resources resulted in lower costs, fewer hospital admissions, and higher patient satisfaction scores for Crystal Run Healthcare.

A triplet combining the PD-1 inhibitor spartalizumab with dabrafenib and trametinib led to a 12-month overall survival rate of 86.1% for patients with previously untreated advanced BRAF V600–mutant melanoma.

Immunotherapy prescriptions for patients with metastatic bladder cancer declined rapidly after the FDA altered the indications of 2 drugs, suggesting that oncologists can keep pace with changes associated with the agency’s accelerated approval program.

The combination of cobimetinib (Cotellic) and vemurafenib (Zelboraf) maintained an advantage for overall survival and objective response rate in patients with BRAF-positive melanoma versus vemurafenib alone.